Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

23-02-2022 | ASCO GU 2022 | Conference coverage | Video

MAGNITUDE shows benefit of add-on niraparib for mutated mCRPC

Gerhardt Attard tells us why he is excited about the results of the MAGNITUDE trial evaluating the upfront addition of niraparib to abiraterone acetate in men with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations (5:11).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

18-02-2022 | ASCO GU 2022 | Conference coverage | News

​​​​​​​PROpel: mCRPC patients benefit from add-on olaparib

10-02-2022 | Prostate cancer | News

Niraparib promising in patients with mCRPC and DNA repair gene defects

17-02-2022 | Prostate cancer | News

Health-related QoL data support olaparib use in HRR-mutated mCRPC

29-05-2020 | FDA | News

FDA approves rucaparib, olaparib for mutated metastatic CRPC
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits